NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

NEXT STORY
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
PREV STORY
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

NEXT STORY
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
PREV STORY
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

author_avatar
NASDAQ Market News

MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting

ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- – MacroGenics, Inc. (NASDAQ: MGNX), a ...

author_avatar
NASDAQ Market News

Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury

- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 ...

author_avatar
NASDAQ Market News